Chiyuki Okuda

740 total citations
33 papers, 592 citations indexed

About

Chiyuki Okuda is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Chiyuki Okuda has authored 33 papers receiving a total of 592 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Chiyuki Okuda's work include Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Research Studies (10 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Chiyuki Okuda is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Research Studies (10 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Chiyuki Okuda collaborates with scholars based in Japan, Canada and Italy. Chiyuki Okuda's co-authors include Katsuhiro Masago, Reiko Kaji, Akito Hata, Yuichi Sakamori, Michiaki Mishima, Yosuke Togashi, Shiro Fujita, Young Hak Kim, Nobuyuki Katakami and Nobuyuki Katakami and has published in prestigious journals such as PLoS ONE, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Chiyuki Okuda

32 papers receiving 589 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Chiyuki Okuda 350 298 107 84 82 33 592
Fabian Wolpert 210 0.6× 202 0.7× 105 1.0× 38 0.5× 39 0.5× 30 494
A. Katzenwadel 228 0.7× 122 0.4× 133 1.2× 46 0.5× 56 0.7× 23 548
Jame Abraham 476 1.4× 164 0.6× 71 0.7× 45 0.5× 34 0.4× 35 660
Francisco Martínez‐Ricarte 168 0.5× 111 0.4× 174 1.6× 251 3.0× 68 0.8× 33 778
Yuan Yang 60 0.2× 94 0.3× 172 1.6× 135 1.6× 56 0.7× 38 512
Elmar Heinrich 328 0.9× 138 0.5× 110 1.0× 46 0.5× 21 0.3× 28 555
Narihiko Hayashi 352 1.0× 138 0.5× 157 1.5× 67 0.8× 70 0.9× 45 582
Tom van den Ende 168 0.5× 167 0.6× 117 1.1× 70 0.8× 38 0.5× 27 512
Mary Welch 92 0.3× 108 0.4× 64 0.6× 57 0.7× 35 0.4× 37 405
Refika Yigit 218 0.6× 254 0.9× 54 0.5× 39 0.5× 46 0.6× 18 712

Countries citing papers authored by Chiyuki Okuda

Since Specialization
Citations

This map shows the geographic impact of Chiyuki Okuda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chiyuki Okuda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chiyuki Okuda more than expected).

Fields of papers citing papers by Chiyuki Okuda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chiyuki Okuda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chiyuki Okuda. The network helps show where Chiyuki Okuda may publish in the future.

Co-authorship network of co-authors of Chiyuki Okuda

This figure shows the co-authorship network connecting the top 25 collaborators of Chiyuki Okuda. A scholar is included among the top collaborators of Chiyuki Okuda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chiyuki Okuda. Chiyuki Okuda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Masago, Katsuhiro, Shiro Fujita, Akito Hata, et al.. (2017). PD-L1 Expression in Patients with Non-small Cell Lung Cancer. Anticancer Research. 37(5). 2269–2274. 3 indexed citations
2.
Nanjo, Shigeki, Akito Hata, Chiyuki Okuda, et al.. (2017). Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer. British Journal of Cancer. 118(1). 32–37. 69 indexed citations
3.
Hata, Akito, Nobuyuki Katakami, Shigeki Nanjo, et al.. (2017). Rebiopsy of Histological Samples in Pretreated Non-small Cell Lung Cancer: Comparison Among Rebiopsy Procedures. In Vivo. 31(3). 475–479. 7 indexed citations
4.
Hata, Akito, Nobuyuki Katakami, Shigeki Nanjo, et al.. (2016). Correlation between programmed death-ligand 1 (PD-L1) expression and T790M status in EGFR-mutant non-small cell lung cancer (NSCLC). Annals of Oncology. 27. vi428–vi428. 1 indexed citations
5.
6.
Otsuka, Kyoko, Akito Hata, Jumpei Takeshita, et al.. (2015). EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 76(4). 835–841. 39 indexed citations
7.
Fujita, Shiro, Katsuhiro Masago, Jumpei Takeshita, et al.. (2015). Validation of an Ion Torrent Sequencing Platform for the Detection of Gene Mutations in Biopsy Specimens from Patients with Non-Small-Cell Lung Cancer. PLoS ONE. 10(6). e0130219–e0130219. 6 indexed citations
8.
Masago, Katsuhiro, Shiro Fujita, Miho Muraki, et al.. (2015). Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations. BMC Cancer. 15(1). 908–908. 27 indexed citations
9.
Masago, Katsuhiro, Daichi Fujimoto, Shiro Fujita, et al.. (2014). Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer. Molecular and Clinical Oncology. 3(2). 415–419. 36 indexed citations
10.
Masago, Katsuhiro, Yosuke Togashi, Shiro Fujita, et al.. (2013). Effect of the <b><i>BCL2</i></b> Gene Polymorphism on Survival in Advanced-Stage Non-Small Cell Lung Cancer Patients Who Received Chemotherapy. Oncology. 84(4). 214–218. 11 indexed citations
11.
Sakamori, Yuichi, Katsuhiro Masago, Katsuyuki Ohmori, et al.. (2012). Increase in circulating endothelial progenitor cells predicts response in patients with advanced non‐small‐cell lung cancer. Cancer Science. 103(6). 1065–1070. 17 indexed citations
12.
Togashi, Yosuke, Katsuhiro Masago, Isao Ito, et al.. (2012). Pneumocystis jiroveci pneumonia and colonization in patients with advanced lung cancer. Oncology Letters. 5(2). 601–604. 9 indexed citations
13.
Kim, Young Hak, Chiyuki Okuda, Yuichi Sakamori, et al.. (2012). Continuous morphine infusion for end-stage lung cancer patients. Oncology Letters. 5(3). 972–974. 5 indexed citations
14.
Kim, Young Hak, Shinji Sumiyoshi, Seiji Hashimoto, et al.. (2012). Expressions of Insulin-Like Growth Factor Receptor-1 and Insulin-Like Growth Factor Binding Protein 3 in Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 13(5). 385–390. 13 indexed citations
15.
Okuda, Chiyuki, Young Hak Kim, Kengo Takeuchi, et al.. (2011). Successful Treatment with Pemetrexed in a Patient with Mucinous Bronchioloalveolar Carcinoma: Long-Term Response Duration with Mild Toxicity. Journal of Thoracic Oncology. 6(3). 641–642. 4 indexed citations
16.
Togashi, Yosuke, Katsuhiro Masago, Yuichi Sakamori, et al.. (2011). Long-term Survival in a Patient with Small-cell Lung Cancer Undergoing Hemodialysis Who Received Multiple Courses of Chemotherapy. Japanese Journal of Clinical Oncology. 41(4). 582–585. 4 indexed citations
17.
Kim, Young Hak, Katsuhiro Masago, Yosuke Togashi, et al.. (2011). EGFR mutation: Significance as a stratification factor in the era of molecular-targeted therapy. Oncology Letters. 2(2). 383–387. 4 indexed citations
18.
19.
Togashi, Yosuke, Katsuhiro Masago, Tomohiro Handa, et al.. (2011). Prognostic Significance of Preexisting Interstitial Lung Disease in Japanese Patients With Small-Cell Lung Cancer. Clinical Lung Cancer. 13(4). 304–311. 29 indexed citations
20.
Masago, Katsuhiro, Shiro Fujita, Yosuke Togashi, et al.. (2010). Clinical Significance of Pretreatment C-Reactive Protein in Patients with Advanced Nonsquamous, Non-Small Cell Lung Cancer Who Received Gefitinib. Oncology. 79(5-6). 355–362. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fabian Wolpert Breakdown of academic impact, for papers by A. Katzenwadel Breakdown of academic impact, for papers by Jame Abraham Breakdown of academic impact, for papers by Francisco Martínez‐Ricarte Breakdown of academic impact, for papers by Yuan Yang Breakdown of academic impact, for papers by Elmar Heinrich Breakdown of academic impact, for papers by Narihiko Hayashi Breakdown of academic impact, for papers by Tom van den Ende Breakdown of academic impact, for papers by Mary Welch Breakdown of academic impact, for papers by Refika Yigit
Rankless by CCL
2026